[CAS NO. 52549-17-4] Pranoprofen

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [52549-17-4]

Catalog

HY-B0336

Brand

MCE

CAS

52549-17-4

DESCRIPTION [52549-17-4]

Overview

MDL	MFCD00866111
Molecular Weight	255.27
Molecular Formula	C15H13NO3
SMILES	CC(C(O)=O)C1=CC2=C(C=C1)OC3=NC=CC=C3C2

For research use only. We do not sell to patients.

Summary

Pranoprofen is a non-steroidal anti-inflammatory agent ( NSAID ) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit COX-1 and COX-2 enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis ^[1] ^[2] .

IC50 & Target

COX-1

COX-2

In Vitro

Pranoprofen (pretreatment for 1 h; 1 mM) has an inhibitory effect against ER stress-induced GRP78 and CHOP expression in glial cells ^[1] .
Pranoprofen (5-25 µM; 24 h) dose-dependently enhances Dicer expression. Additionally, Pranoprofen at 5 µM enhances H2O2 (800 µM)-induced Dicer expression in FHC cells ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pranoprofen (oral administration; 4 mg/kg/16 mg/kg; 9 days) rescues Dicer expression in inflamed colon tissues, alleviates colitis and prevents colitis-associated colon cancers in C57BL/6 mice ^[3] .
Dicer is a key component of the RNA interference pathway and is essential for the biogenesis of miRNAs and siRNAs.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS-induced acute colitis in C57BL/6 mice ^[3]
Dosage:	4 mg/kg;16 mg/kg
Administration:	Oral administration; 4 mg/kg/16 mg/kg; 9 days
Result:	Alleviated inflammation in DSS-induced acute colitis.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03355638	Università degli Studi di Brescia	Macular Edema	January 2016	Phase 4
NCT03013959	Peking Union Medical College	Keratitis, Herpetic	November 2016
NCT03712670	Università degli Studi di Brescia	Retinal Disease	January 1, 2016	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 391.74 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9174 mL	19.5871 mL	39.1742 mL
5 mM	0.7835 mL	3.9174 mL	7.8348 mL
10 mM	0.3917 mL	1.9587 mL	3.9174 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, α-methyl-

α-Methyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetic acid

Y 8004

2-(5H-[1]-Benzopyrano[2,3-b]pyridin-7-yl)propionic acid

Pranoprofen

Niflan

α-Methyl-5H-[1]benzopyrano[2,3-b]pyridine-7-ylacetic acid

(±)-Pranoprofen

(RS)-Pranoprofen

dl-Pranoprofen

Oftalar

2-(5H-Chromeno[2,3-b]pyridin-7-yl)propanoic acid